Our Research

Research
Houston Methodist COVID-19 Research Thumbnail
Coronavirus Disease 2019 (COVID-19) Research

Houston Methodist researchers are studying the novel coronavirus disease 2019. Read more...

At Houston Methodist, fostering innovations with the potential for clinical application is at the very heart of what we do. Our interdisciplinary teams of clinicians and researchers are committed to streamlining the process of translating discoveries into treatments and cures for our patients.

 

Learn more about how we are delivering on our commitment to leading medicine from the earliest phase of discovery in a lab to the testing new drugs or therapies in clinical trials.

 

Our VIEW BOOK



You can find our most recent annual report here: 2021 HMAI Annual Report

Novel medical technology for craniomaxillofacial surgery is cleared by FDA for market

Doctor using AnatomicAligner, a new FDA-approved Methodist-built software program, on an iPad.

Houston Methodist recently reached a major milestone, receiving U.S. Food and Drug Administration (FDA) 510(k) clearance to market the AnatomicAligner, a novel, comprehensive software program used to improve planning for craniomaxillofacial (CMF) surgeries. Learn more>

Houston Methodist is first to treat COVID-19 with convalescent plasma therapy

Computer-generated image of a Coronavirus

Houston Methodist was the first in the nation to receive FDA approval to use convalescent plasma for COVID-19 patients and the first to publish a peer-reviewed study on the therapy, revealing 19 of 25 critically ill patients showed improvement. Learn more>

 

Researchers Identify Protein To Aid With Glioblastomas

Molecular Analysis Slide

In a recent study published in Nature Communications, Houston Methodist researchers, led by Kyuson Yun, PhD, associate professor of neurology, conducted a molecular analysis that identified a protein, S100A4, which could be a therapeutic target for restoring anti-tumor action of immune cells toward glioblastomas that have beguiled the immune system into protecting it.  Learn more>

Center for RNA Therapeutics Awarded Inno Fire Award

Inno Fire Awards Logo

The Center for RNA Therapeutics won the 2022 Houston Inno Fire Award from the Houston Business Journal for innovation in health care and life sciences. Learn more>

 

Latest News

Monday, June 5, 2023 New analysis shows COVID variant and severity of illness influence cardiac dysfunction, a key indicator of long COVID
Patients infected with beta and delta COVID-19 variants, and those who required hospital stays for COVID-19 infection, were more likely to experience heart issues associated with long COVID, according to a recent study published in the European Heart Journal - Cardiovascular Imaging. Patients recove...
Read more
Monday, April 24, 2023 Houston researchers successfully reverse infertility in mice
Read more
Wednesday, April 19, 2023 Study suggests longer time between COVID-19 vaccines more effective for some
With the FDA authorizing a second bivalent booster this week for individuals at high risk from COVID-19 and the CDC expected to sign off on it, as well, a recent Houston Methodist study may offer some guidance on when certain populations should get that next booster. A research team of computational...
Read more
View All News & Events
More to Explore
Find Faculty
Find Core Facilities
Explore Faculty Labs
Read Methodology